Arch Biopartners (ARCH) AI Stock Analysis

• Market Cap: C$36.81M
• Dividend Yield: N/A
• Average Volume (3M): 43.97K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.85
• Revenue Growth: N/A
• EPS Growth: 10.49%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 66,933,290
• 10 Day Avg. Volume: 31,059
• 30 Day Avg. Volume: 43,967
• PEG Ratio: 0.88
• Price to Book (P/B): -21.63
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -53.01
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -0.16
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: C$0.53 ▼(-61.68% Downside)
• Action: Reiterated Date: 03/26/26
• Date: Action: Reiterated 03/26/26

The score is driven primarily by weak financial performance (no TTM revenue, ongoing losses, negative equity, and continued cash burn). Technical indicators also reflect a pronounced downtrend and weak momentum, while valuation metrics provide limited support given the negative earnings and lack of dividend data.

Positive Factors

Focused therapeutic platform

A platform-focused R&D approach (DPEP-1 inhibitor + antibody program) supports reusable science across multiple programs and indications. That structural setup improves long-term development efficiency, increases licensing appeal, and can create multiple value pathways if one program proves clinical proof-of-concept.

Negative Factors

No revenue and persistent losses

Zero trailing revenue and recurring net losses mean the company cannot self-fund development and must rely on external capital or deals. Over the medium term this elevates dilution and execution risk, and constrains the ability to advance multiple programs simultaneously without partner funding or financings.

Arch Biopartners Business Overview & Revenue Model

Company Description

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or...

Read more

Arch Biopartners Inc., a biotechnology company, develops technologies for medical or commercial impact. It focuses on developing its lead drug candidate Metablok to treat or prevent dipeptidase-1 mediated organ inflammation in the lungs, liver, or...

How the Company Makes Money

Arch Biopartners does not appear to be a commercial-stage company and, based on publicly available high-level disclosures, it has not indicated recurring product sales as a primary source of revenue. Its typical expected ways of generating revenue...

Read more

Arch Biopartners does not appear to be a commercial-stage company and, based on publicly available high-level disclosures, it has not indicated recurring product sales as a primary source of revenue. Its typical expected ways of generating revenue...

Arch Biopartners Financial Statement Overview

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	2.12M	1.98M	964.68K	3.89M
Gross Profit	0.00	-1.66M	-129.00K	-503.00K	-150.00K
EBITDA	-1.29M	-3.53M	-336.00K	-101.00K	-77.02K
Net Income	-1.55M	-3.92M	-3.33M	-1.41M	-1.17M
Balance Sheet
Total Assets	104.53K	935.62K	1.17M	621.64K	2.67M
Cash, Cash Equivalents and Short-Term Investments	2.10K	2.97K	831.27K	506.35K	448.24K
Total Debt	2.84M	2.77M	5.02M	4.41M	5.16M
Total Liabilities	3.99M	5.28M	6.68M	5.09M	6.55M
Stockholders Equity	-3.88M	-4.35M	-5.51M	-4.47M	-3.88M
Cash Flow
Free Cash Flow	-1.58M	-2.33M	-234.08K	-1.08M	-2.98M
Operating Cash Flow	-1.58M	-2.33M	-234.07K	-1.08M	-2.98M
Investing Cash Flow	0.00	0.00	0.00	0.00	0.00
Financing Cash Flow	1.58M	1.50M	559.00K	-421.37K	2.78M

Arch Biopartners Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.37
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ARCH, the sentiment is Negative. The current price of 1.37 is above the 20-day moving average (MA) of 0.72, above the 50-day MA of 0.92, and above the 200-day MA of 1.30, indicating a bearish trend. The MACD of -0.09 indicates Positive momentum. The RSI at 22.17 is Positive, neither overbought nor oversold. The STOCH value of 8.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:ARCH.

Arch Biopartners Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MSCL	46 Neutral	C$152.27M	-5.03	-89.10%	―	―	27.53%
BCT	46 Neutral	C$40.46M	-0.41	-205.87%	―	―	62.01%
MDNA	42 Neutral	C$42.61M	-4.40	-103.51%	―	―	54.74%
ARCH	41 Neutral	C$36.81M	-12.93	72.34%	―	―	10.49%